A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
← catalyst calendarNCT05538130 · readout in 348 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
124estimated
Sites
83
Countries
Australia, Brazil, Canada +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-11-30 | actual | When the study began enrolling |
| Primary completion | 2027-08-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-06-18 | estimated | The whole study's end, after follow-up |
| First posted | 2022-09-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Melanoma
- Glioma
- Thyroid Cancer
- Non-Small Cell Lung Cancer
- Malignant Neoplasms
- Brain Neoplasms
- Advanced or Metastatic Solid Tumors
- HGG
- LGG
- Low Grade Glioma
- High Grade Glioma
- Differentiated Thyroid Cancer
- NSCLC (Non-small Cell Lung Cancer)
Interventions
- Drug: PF-07799544 — also filed as ARRY-134
- Drug: PF-07799933 — also filed as ARRY-440
Primary outcomes
what the primary-completion date above is the date OFPhase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with dose limiting toxicities (DLTs)
measured Cycle 1 (21 days)
Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with treatment-emergent adverse events (AEs)
measured Baseline to 28 days after last dose of study medication
Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with clinically significant change from baseline in laboratory abnormalities
measured Baseline to 28 days after last dose of study treatment
Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with clinically significant change from baseline in vital sign abnormalities
measured Baseline to 28 days after last dose of study treatment
Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with clinically significant change from baseline in physical exam abnormalities
measured Baseline to 28 days after last dose of study treatment
Phase 1b Dose Expansion: Overall response rate (ORR)
measured Baseline to 2 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed